Home Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results
 

Keywords :   


Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results

2015-07-13 18:14:55| Biotech - Topix.net

Gilead Sciences shares have once again seen a pullback in the last three weeks. Since June 24th, the stock is down nearly 7%, presenting another good opportunity to buy.

Tags: results reports novo digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11 ( #1670 )
27.1117 AIR AGS 83M-S
27.11 XYZ 3
27.11XVSecret1
27.11NFT ADVANCE 3-370!
27.11 101
27.11
27.11 DESCENTE L
More »